SGLT2 inhibitors suppress reabsorption of glucose by inhibition of SGLT2, and thereby increase urinary glucose excretion by approximately 60–80 g per day and ameliorate hyperglycemia [3]. The gene discussed is SLC5A2; the disease is Hyperglycemia.